Article Text
Abstract
Neurocognitive enhancement, or cosmetic neurology, offers the prospect of improving the learning, memory and attention skills of healthy individuals well beyond the normal human range. Much has been written about the ethics of such enhancement, but policy-makers in the USA, the UK and Europe have been reluctant to legislate in this rapidly developing field. However, the possibility of discrimination by employers and insurers against individuals who choose not to engage in such enhancement is a serious threat worthy of legislative intervention. While lawmakers should not prevent individuals from freely pursuing neurocognitive enhancement, they should act to ensure that such enhancement is not coerced. This paper offers one model for such legislation, based upon a proposed US law, the Genetic Information Nondiscrimination Act of 2008, to address precisely this particular pitfall of the impending neuroscience revolution.
Statistics from Altmetric.com
Footnotes
Competing interests: None declared.
↵i Chatterjee enumerated the four concerns as relating to safety, character and individuality, distributive justice and coercion. Ronald Bailey had earlier laid out eight objections,14 which neatly overlap with those advanced by Chatterjee. See also Chatterjee (2004).3
Other content recommended for you
- Smart drugs for cognitive enhancement: ethical and pragmatic considerations in the era of cosmetic neurology
- Frequency and individual severity of arterial blood pressure changes in children and adolescents with attention-deficit/hyperactivity disorder treated with methylphenidate hydrochloride: a prospective non-interventional study
- Neurogenetic determinism and the new euphenics
- Ethics briefings
- Clinical trials in mild cognitive impairment: lessons for the future
- ▼Memantine for dementia?
- Methylphenidate hydrochloride reduces hyperactivity in children with pervasive development disorders
- PP-039 Impact of masking on methylphenidate dissolution for over encapsulated capsules of ritalin la 10 mg
- Selected highlights from other veterinary journals
- Feasibility of investigating methylphenidate for the treatment of sarcoidosis-associated fatigue (the FaST-MP study): a double-blind, parallel-arm randomised feasibility trial